中文

RFH02A Vaccine Adjuvant

Adjuvant (Adjuvant), also known as immunomodulator or immunopotentiator (Immunepotentiator), is used as an additive of vaccine. When it is injected into the body before antigen or mixed with antigen, it can enhance the immune response of the body to antigen or change the type of immune response. It belongs to non-specific immune enhancer, but it has no antigenicity.

Classification:

Pharmaceutical excipients for biologics

Telephone:

86-0711-3813176

Message

RFH02A Vaccine Adjuvant

Detailed introduction

1. Product Description

Adjuvant (Adjuvant)Also known as immunomodulator or immunopotentiator (Immunepotentiator), it is used as an additive of vaccine. When it is injected into the body before antigen or mixed with antigen, it can enhance the body's immune response to antigen or change the type of immune response. It is a non-specific immune enhancer, and it has no antigenicity. The ideal adjuvant can not only enhance the immune response, but also make the body obtain the best protective immunity.

RFH02A Adjuvantis an oil-in-water emulsion containing 42.8mg squalene/mL, 19.4mg polysorbate 80/mL,47.5mg tocopherol/mL.

Product Name	English Name	CAS No.	Item No.	Packing specification	Executive standard	CDE Registration Number	FDA Registration Number
RFH02A Vaccine Adjuvant	RFH02A adjuvant	——	F1003-000500	500g/bottle	——	——	——

2. Product advantages

Product quality can meet the requirements of different regulations and market standards;

More high quality assurance: Polysorbate 80(II) uses more than 99% purity oleic acid as raw material, squalene content as high as 99.9%, to ensure the stability of different batches of products;

Higher security: ultrafiltration process, effective removal of bacterial endotoxin; in line with the requirements of vaccine injection;

Good packing: the inner packing material is glass bottle, nitrogen protection, more suitable for injection.

3. Product Application

Vaccine adjuvant improves antigen immunogenicity

1) reduce the frequency of vaccination;

2) reduce the antigen dose of a single vaccine;

3) Improve the intensity of immune response and promote cross-immune protection;

4) In some cases, they can improve the stability of the final vaccine formulation.

4. Characteristic R & D service

1. National Pharmacopoeia Detection Operation Decomposition Guidance

2. Customized specialty preparation services

Key words: